Innovent Biologics says Jaypirca approved in China for CLL/SLL across all lines of therapy
Company says Jaypirca (pirtobrutinib) was approved in China for CLL/SLL across all lines of therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Innovent Biologics Says Jaypirca (Pirtrobrutinib) Approved In China For Cll/Sll Across All Lines Of Therapy
Innovent Biologics, Inc. HKEX:1801